Press releases
- Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
- Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
- Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
More ▼
Key statistics
As of last trade Relmada Therapeutics Inc (4E2:DUS) traded at 3.54, -17.67% below its 52-week high of 4.30, set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.58 |
---|---|
High | 3.58 |
Low | 3.54 |
Bid | 3.66 |
Offer | 3.78 |
Previous close | 3.64 |
Average volume | 0.00 |
---|---|
Shares outstanding | 30.17m |
Free float | 27.75m |
P/E (TTM) | -- |
Market cap | 120.40m USD |
EPS (TTM) | -3.13 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 15:31 BST.
More ▼